Thorsten Lewalter - 2nd Global LAAO Summit: Stroke Risk and Prevention in Atrial Fibrillation: Latest data on new anticoagulants
About this lecture
Stroke Risk and Prevention in Atrial Fibrillation: Latest data on new anticoagulants
Role of 'old and new' drugs. Larger population of patients addressed. New evidence, new drugs. Contra indications and role for alternatives.
- 2nd Global LAAO Summit
Subjects related to this videoClinical Evidence
David Hildick Smith - What’s new: clinical data published and presented since last year
New clinical data for left atrial appendage occlusion therapy, presented & published in 2016. Includes a critical review of the Stroke Prevention section in the 2016 ESC Atrial Fibrillation guidelines.
Matthew Price - What’s new: cost effectiveness and health economics
Why might LAA occlusion therapy be cost effective, despite a high procedural cost? This presentation is an overview of the health economics data available for left atrial appendage closure therapy.
John Camm, Hans Christop Diener - Debate: Are the new ESC guidelines too strict for LAA Occlusion?
John Camm, UK vs Hans Christoph Diener, DEU Debate: Are the new ESC guidelines are too strict for Left Atrial Appendage Occlusion? John Camm - Yes, they are too strict. There is a larger group that should benefit from LAA occlusion and it should be stronger recommended too!Hans Christoph Diener - No, the ESC guidelines are right; LAA occlusion Should be limited to OAC contraindicated patients!